Anti-SARS CoV-2 inhibitors by dual viral-host targeting
The present invention discloses novel SARS-CoV-2 inhibitors for therapeutic formulations and methods for treating SARS-CoV-2 infections. The compounds exhibit unique pharmacophoric features including conformational flexibility and spatial orientation within the binding sites of the targeted proteases. The present invention also discloses methods for treating SARS-CoV-2 infections, comprising administering to the subject in need thereof a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutical excipients.
1. The compound according to Formula 13M, or pharmaceutically acceptable salt thereof:
2. A pharmaceutical composition, comprising a therapeutically effective amount of the compound of claim 1 , or pharmaceutically acceptable salts thereof, and one or more pharmaceutical excipients.
3. A method of treating a subject afflicted by SARS-CoV-2, comprising administering to the subject in need thereof a therapeutically effective amount of Formula 13M or a pharmaceutically acceptable salt thereof and one or more pharmaceutical excipients.
4. The method of claim 3 , wherein the subject is a mammal.
5. The method of claim 4 , wherein the mammal is a human.